Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients

Table 5

RAVs to nonnucleoside NS5B inhibitors.

Resistance mutations	Drugs	Reference	Detected resistance mutations	Detected resistance mutations
Case number
C316Y/N/H	Dasabuvir, tegobuvir, HCV796	[13–16, 34]	—	C316N 100% (60/60)
S365T/A	Tegobuvir, HCV796	[15, 16]	S365F 1.2% (1/82); S365P 1.2% (1/82)	S365A 3.33% (2/60)
S368T	Dasabuvir	[14]	S368A 1.2% (1/82); S368L 1.2% (1/82)	—
Case number
M414T/I/V/L	Dasabuvir, tegobuvir, HCV796	[13, 15, 16]	M414Q 50% (2/4)	M414L 5.88% (3/51)
L419M/V	Tegobuvir, HCV796	[15, 16]	L419I 100% (4/4)	—
M423T/I/V	Tegobuvir, HCV796	[15, 16]	—	M423I 1.96% (1/51)
Y448C/H	Dasabuvir, tegobuvir	[13–16]	—	Y448H 1.96% (1/51)
I482L/V/T	Tegobuvir	[15, 16]	I482L 100% (4/4)	I482T 5.88% (3/51); I482V 1.96% (1/51)
V494S/Q/L/A/T	Tegobuvir	[15, 16]	V494A 50% (2/4); V494C 25% (1/4)	V494L 3.92% (2/51)
P495S/Q/L/A/T	Tegobuvir	[15, 16]	—	P495S 5.88% (3/51)
P496A/S	Tegobuvir	[15, 16]	—	P496T 5.88% (3/51)
V499A	JTK-109, deleobuvir	[15]	V499A 100% (4/4)	V499A 15.69% (8/51); V499T 1.96% (1/51); V499I 3.92% (2/51)